CAMBRIDGE, Mass.--(BUSINESS WIRE)--Dec. 13, 2005--EPIX Pharmaceuticals, Inc. (NASDAQ: EPIX) announced today that, as a result of the FDA’s second approvable letter regarding Vasovist(TM), it will eliminate approximately 50% of its workforce in January, 2006. The reductions will affect both the research and development and the general and administrative areas of the Company. Prior to the initial announcement on November 23, 2005 of the Company’s intention to reduce its workforce, the Company had 93 employees. Following the completion of the reduction, the Company expects that it will have approximately 48 employees.
